Devin Jopp’s Post

📃Scientific paper: Outbreak of colistin and carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-48 isolates in an Iranian hospital Abstract: Background Colistin and carbapenem-resistant Klebsiella pneumoniae (Col-CRKP) represent a significant and constantly growing threat to global public health. We report here an outbreak of Col-CRKP infections during the fifth wave of COVID-19 pandemic. Methods The outbreak occurred in an intensive care unit with 22 beds at a teaching university hospital, Isfahan, Iran. We collected eight Col-CRKP strains from seven patients and characterized these strains for their antimicrobial susceptibility, determination of hypermucoviscous phenotype, capsular serotyping, molecular detection of virulence and resistance genes. Clonal relatedness of the isolates was performed using MLST. Results The COVID-19 patients were aged 24–75 years with at least 50% pulmonary involvement and were admitted to the intensive care unit. They all had superinfection caused by Col-CRKP, and poor responses to antibiotic treatment and died. With the exception of one isolate that belonged to the ST11, all seven representative Col-CRKP strains belonged to the ST16. Of these eight isolates, one ST16 isolate carried the iucA and ybtS genes was identified as serotype K20 hypervirulent Col-CRKP. The bla _SHV and bla _NDM-1 genes were the most prevalent resistance genes, followed by bla _OXA-48 and bla _CTX-M-15 and bla _TEM genes. Mobilized colistin-resistance genes were not detected in the isolates. Conclusions The continual emergence of ST16 Col-CRKP strains is a major threat to public health worldwide... Continued on ES/IODE ➡️ https://etcse.fr/mjcS ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Antimicrobial resistance (AMR) is a growing and global threat to public health that jeopardizes decades of progress in the fight against bacterial infections. This phenomenon occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines. Consequently, antibiotics become less effective in treating bacterial infections, making them more difficult to manage and increasing the risk of severe illness and death. The issue of antimicrobial resistance was also the main focus at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which was held in Barcelona from 27th to 30th April. To learn more, read our latest article on the blog 👉 https://lnkd.in/dp-xpZWf #Menarini #antimicrobialresistance #AMR #ECCMID

🔬🦠 The battle against antimicrobial resistance (AMR) hinges on rapid and accurate diagnostics. This article by Pavillion Health Today highlights some key takeaways from the recent ESCMID - European Society of Clinical Microbiology and Infectious Diseases Global Congress where experts discussed why diagnostics are essential for identifying drug-resistant pathogens quickly, ensuring appropriate treatments, and reducing the misuse of antibiotics. Innovations and advancements in diagnostic technologies are key to tackling AMR and improving patient health outcomes. Learn more: https://lnkd.in/eSV4Razn #AntimicrobialResistance #AMR #PioneeringDiagnostics

Key Developments in Antimicrobial Resistance: Addressing #Antimicrobialresistance (AMR) is crucial for global health. When microbes become resistant to medications, treating infections becomes challenging, leading to more severe illnesses and increased mortality rates. Here are the latest advancements in combating AMR: - WHO's Global Research Agenda: The #WHO has launched a comprehensive global research agenda focusing on drug-resistant bacteria, fungi, and tuberculosis. By 2030, 40 key research topics will be addressed to drive innovation and enhance understanding, diagnostics, and treatments for AMR. - Innovative Scientific Approaches: The DARTS project aims to combat antibiotic resistance by creating new antibiotic options, improving diagnostics, and enhancing infection treatment. This initiative strives to make treating infections more effective and affordable. - Rising Resistance in Common Infections: Recent reports highlight alarming trends in AMR, showing high resistance levels in severe bloodstream infections and common bacterial infections. This underscores the urgent need for better data and strategies to address AMR effectively. - The Impact of COVID-19: The pandemic has exacerbated the AMR crisis, with a 20% increase in antibiotic-resistant bacterial infections during COVID-19. Enhanced vigilance and infection control measures are crucial to mitigate this growing concern. - New Therapeutic Strategies: Researchers are exploring novel approaches, such as developing new antibiotics, alternative treatments, and comprehensive strategies to combat resistance. These efforts target specific resistant microbes and aim to manage AMR effectively. In conclusion, tackling AMR is a collaborative global endeavor that necessitates ongoing research, innovative solutions, and effective policies. Staying informed and supporting these initiatives are vital in preserving the efficacy of antimicrobial medicines and safeguarding public health. #antibiotics #microbiology #clinicalresearch #medicalinnovation

Antifungal Resistance is a growing concern and we need to let the world know. 🧫Fungal infections, once considered less threatening compared to bacterial or viral infections, have gained attention in recent years due to the rise of antifungal resistance. Antifungal resistance occurs when fungi develop mechanisms to evade the effects of antifungal medications, rendering them less effective or ineffective in treating fungal infections. This phenomenon poses a significant challenge to public health worldwide and requires a comprehensive understanding of its mechanisms, implications, and strategies to mitigate its impact. 🧫This resistance can arise through various mechanisms, including mutations in the fungal target site, overexpression of drug efflux pumps, or changes in cell membrane permeability. It poses a significant challenge in the treatment of fungal infections and requires ongoing research and surveillance to address. 🧫Addressing this issue requires a coordinated effort involving healthcare professionals, researchers, policymakers, and the pharmaceutical industry. By implementing comprehensive strategies focused on surveillance, infection control, antimicrobial stewardship, and research and development, we can mitigate the impact of antifungal resistance and safeguard the effectiveness of antifungal therapy for future generations. #antifungalresistance #nawiriafrica

⚠ Case Study: Dual Infection in a Sputum Sample -Patient Age: 75 years -Sample Type: Sputum -Identified Pathogens: Heavy Klebsiella pneumoniae and Heavy Serratia marcescens During my training at the Microbiology Lab, I encountered an interesting case involving a 75-year-old patient presenting with severe respiratory distress. The sputum sample showed heavy growth of both Klebsiella pneumoniae and Serratia marcescens, isolated on blood agar. These bacteria are common causes of hospital-acquired infections, especially in patients with weakened immune systems. Microbiological Findings: -Klebsiella pneumoniae: Recognizable by its heavy, mucoid colonies due to the polysaccharide capsule, which enhances virulence and protects it from phagocytosis. -Serratia marcescens: Known for its occasional production of a distinctive red pigment, this bacterium was also isolated in significant amounts, further complicating the patient’s condition. Clinical Relevance: These Gram-negative organisms are both important in nosocomial infections, particularly in pneumonia and sepsis. Both pathogens were subjected to antibiotic sensitivity testing, and a tailored treatment plan was initiated. Treatment Challenges Given the high risk of multi-drug resistant (MDR) strains, especially in Klebsiella species, careful selection of antibiotics was critical in this case. Treatment was started with a combination of antibiotics targeting both MDR Klebsiella and Serratia strains. Did You Know? Infections caused by Klebsiella pneumoniae, particularly resistant strains, are associated with significant mortality in elderly patients. According to the CDC, antibiotic-resistant Klebsiella is becoming a serious global threat, especially in healthcare settings. Let’s Discuss! Have you encountered co-infections of this nature? How do you approach cases with multi-drug resistant pathogens in your practice? Let’s discuss the latest antibiotic stewardship strategies and their impact on managing such complex infections. #Microbiology #LabScience #InfectiousDiseases #AntibioticResistance #ClinicalMicrobiology #Healthcare

Antibiotic resistance occurs when bacteria develop the ability to withstand the effects of antibiotics, making them ineffective against infections. This is a growing global concern, as it: 1. Reduces treatment options 2. Increases the risk of untreatable infections 3. Prolongs hospital stays 4. Increases healthcare costs 5. Threatens public health Causes of antibiotic resistance: 1. Overuse and misuse of antibiotics 2. Poor infection control practices 3. Lack of new antibiotic development 4. Genetic mutation and adaptation 5. Horizontal gene transfer (bacteria sharing resistance genes) Consequences of antibiotic resistance: 1. Increased mortality rates 2. Prolonged illnesses 3. Increased healthcare costs 4. Reduced effectiveness of medical treatments (e.g., organ transplants, cancer chemotherapy) 5. Economic burdens To combat antibiotic resistance: 1. Use antibiotics judiciously and only when necessary 2. Implement infection control practices (e.g., hand hygiene, sterilization) 3. Develop new antibiotics and alternative treatments 4. Improve antibiotic stewardship programs 5. Enhance public awareness and education 6. Encourage responsible use of antibiotics in agriculture and animal husbandry By understanding the causes and consequences of antibiotic resistance, we can work together to mitigate this growing threat and ensure effective treatments for future generations. #MedicalLaboratoryTechnology #Microbiology #Phlebotomy #LaboratoryTesting #DiagnosticTesting #HealthcareProfessional #MedicalTesting #ClinicalLaboratory #BiomedicalScience #HealthcareIndustry #MedicalScience #LaboratoryMedicine #ClinicalMicrobiology #InfectionControl #PhlebotomyTechnician #MedicalLabTechnician #MicrobiologyLab #ClinicalLab #HealthcareCareer #MedicalCareer #ScienceCareer #COVID19Testing #Virology #Bacteriology #Parasitology #MolecularDiagnosis #GeneticTesting #Cytology #Histopathology #Immunology #Serology

Clostridioides difficile infection (CDI) remains the most common healthcare-associated infection and is associated with significant morbidity. Ridinilazole, a bis-benzimidazole bactericidal antibiotic that preferentially binds to AATTT-rich sequences in the C. difficile DNA minor groove impacting downstream cell septum formation and, likely, the ability to generate ATP. It is highly active against C. difficile and displays targeted activity against C-difficile with minimal inhibitory concentration 90 values of 0.125–0.25 mg/L compared to 0.5–8 mg/L for vancomycin. The product is designed to reduce the recurrence of CDI. A Randomized, Double-Blind, Phase 3 study conducted on CDI patients with positive stool toxin test to receive 10 days of ridinilazole (200 mg twice daily) or vancomycin (125 mg 4 times daily. The study concluded that Ridinilazole greatly reduced rCDI and preserved microbiome diversity and SBAs compared with vancomycin. #link for more detail view this article. https://lnkd.in/dArpGqgm #infectiousdiseases #infectionprevention #infectioncontrol #microbiology #microorganisms #bacteria #difficileinfections #pharmacist #clinicalpharmacist #research #clinicaltrials #clinicalresearch #drugs #investigationalproduct #ResearchPharmacist #doctors #physician #healthcareeducation #healthcareprofessionals

600,000,000 people have the potential to benefit from moxidectin for strongyloidiasis. 200,000,000 people live in onchocerciasis endemic regions and 860,000,000 people live in lymphatic filariasis endemic regions - modeling suggests moxidectin may lead to faster eliminination of disease transmission for these illnesses than the existing standard of care. The potential #globalhealth impact of moxidectin is staggering. Help Medicines Development for Global Health turn the promise into a reality https://lnkd.in/gcxfqu_F

Learn first hand how Soapy, Intelligent Hand Hygiene System can help stop the spread of disease one hand wash at a time. Soapy - Clean Hands, Clean Data #infectionprevention #handhygiene GOJO, Makers of PURELL Ecolab APIC Society for Healthcare Epidemiology of America (SHEA)